Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Raw Materials (2016 - 2021)

Guided Therapeutics' Raw Materials history spans 8 years, with the latest figure at $1.3 million for Q1 2021.

  • On a quarterly basis, Raw Materials rose 63.09% to $1.3 million in Q1 2021 year-over-year; TTM through Mar 2021 was $1.3 million, a 63.09% increase, with the full-year FY2020 number at $1.3 million, up 63.38% from a year prior.
  • Raw Materials hit $1.3 million in Q1 2021 for Guided Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • Over the last five years, Raw Materials for GTHP hit a ceiling of $1.3 million in Q1 2021 and a floor of $781000.0 in Q1 2019.
  • Historically, Raw Materials has averaged $844294.1 across 5 years, with a median of $789000.0 in 2017.
  • Biggest five-year swings in Raw Materials: fell 7.77% in 2017 and later surged 63.38% in 2020.
  • Tracing GTHP's Raw Materials over 5 years: stood at $789000.0 in 2017, then decreased by 0.76% to $783000.0 in 2018, then dropped by 0.26% to $781000.0 in 2019, then surged by 63.38% to $1.3 million in 2020, then grew by 0.08% to $1.3 million in 2021.
  • Business Quant data shows Raw Materials for GTHP at $1.3 million in Q1 2021, $1.3 million in Q4 2020, and $782000.0 in Q3 2020.